Reversal of thermal hyperalgesia in a rat partial sciatic nerve ligation model by Prosaptide TX14(A).

Abstract

We used the partial sciatic nerve ligation (PSL) model of Seltzer to assess thermal hyperalgesia after administration of Prosaptide 14-mer, TX14(A). At a dose of 200 microg/kg in Wistar rats, subcutaneous delivery of TX14(A) reversed thermal hyperalgesia at 3 and 24 h. Values declined at 48 h and returned to baseline at 72 h. A dosing study of TX(14)A gave a dependent response with 100 microg/kg having a similar potency to the 200 microg/kg study with 50 and 10 microg/kg responding somewhat lower. When TX(14)A was administered every fourth day for 12 days at 100 microg/kg, 24 h post injection values returned to baseline each time. Our results suggest that Prosaptide may have potential for therapeutic use in neuropathic pain syndromes in humans.

• Authors: D A Otero, B Conrad, J S O'Brien
• Journal: Neuroscience letters (Neurosci Lett) Vol. 270 Issue 1 Pg. 29-32 (Jul 23 1999) ISSN: 0304-3940 [Print] Ireland
• PMID: 10454138 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Nerve Growth Factors
• prosaptide

Topics

• Amino Acid Sequence
• Animals
• Dose-Response Relationship, Drug
• Hot Temperature
• Hyperalgesia (physiopathology, prevention & control, therapy)
• Molecular Sequence Data
• Nerve Growth Factors (chemistry, therapeutic use)
• Rats
• Rats, Wistar
• Sciatic Nerve (physiology, physiopathology)
• Time Factors